Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders
3 February 2023
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Aflibercept, Anti-VEGF, Dexamethasone implant, Diabetic macular oedema, Persistent, Ranibizumab, Resistant
This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
3 October 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Long term, Macular atrophy, neovascular age-related macular degeneration
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
Management of diabetic macular oedema (DMO)
1 February 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Diabetic macular edema, Steroids
The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
EYE - Pathology, EYE - Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
